ClinicalTrials.gg
Active, not recruitingNCT05617677POETYK SLE-1Updated Dec 3, 2025

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

A Phase 3 interventional study of Deucravacitinib and Placebo in Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Active, not recruiting at 197 sites in 22 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
516
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.

Enrollment
2nd of 19
516 · median 125
Started
2023
with 3 others
Phase 3
3 of 20
1 open now
Registered
11th of 20
by date

Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 3, and was the 11th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Autoimmune Diseases
  • Immune System Diseases
  • Connective Tissue Diseases
  • Immune-mediated Diseases
  • Active Systemic Lupus Erythematosus
  • Lupus
  • SLE
  • Deucravacitinib
  • Tyk2
  • POETYK
  • POETYK SLE
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Systemic Lupus Erythematosus (SLE) at least 24 weeks before the screening visit.
  • Meet the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for SLE.
  • One of the following: positive antinuclear antibodies (ANA) ≥ 1:80 at screening OR positive anti dsDNA OR positive anti Smith (anti Sm) as determined by the central laboratory at screening.
  • Total Systemic Lupus Erythematosus Disease Activity Index-2K (SLEDAI-2K) score ≥ 6 points and clinical SLEDAI 2K score ≥ 4 points with joint involvement, and/or cutaneous vasculitis, and/or rash.
  • Lupus headache, alopecia, organic brain syndrome, and mucosal ulcers must be recorded on SLEDAI 2K, if indicated, but do not count toward the points required for screening at entry.
  • At least one SLE background therapy ( and/or antimalarial) is required for ≥ 12 weeks before the screening visit, must be at a stable dose for ≥ 8 weeks before the screening visit, and must remain stable until randomization and throughout study participation.
  • Oral (OCS; prednisone or equivalent) background therapy is permitted but not required. For participants taking OCS, the dose must be stable for ≥ 2 weeks before the screening visit, cannot exceed 30 mg/day at screening, and must remain stable until the Week 4 visit. Participants can be on an OCS as well as an antimalarial and/or an immunosuppressant.

Exclusion criteria

Exclusion Criteria

  • Diagnosis of drug-induced SLE rather than idiopathic SLE.
  • Other diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc.) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded.
  • SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease are excluded.
  • Active or unstable lupus neuropsychiatric manifestations, including, but not limited to, any condition defined by BILAG A criteria.
  • Active, severe Class III, and IV, lupus nephritis that requires or may require treatment with cytotoxic agents or high-dose CS.
  • History of congenital or acquired immunodeficiency.
  • Known active infection, or any major episode of infection requiring hospitalization or treatment with parenteral (intramuscular or IV) antimicrobial agents (eg, antibiotics antiviral, antifungal, or antiparasitic agents) within 30 days of randomization, or treatment with oral antimicrobial agents within 2 weeks of randomization.
  • Currently on any therapy for chronic infection (eg, pneumocystis, herpes zoster, cytomegalovirus, invasive bacterial or fungal infections, or atypical mycobacteria).
  • Taking more than 1 at screening.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
516 participants (actual)

Study arms

  • Experimental
    Arm 1: Deucravacitinib

    Drug: Deucravacitinib

  • Placebo comparator
    Arm 2: Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve Systemic Lupus Erythematosus Responder Index-4 [SRI(4)] response

    Time frame: At week 52

Secondary outcomes

  1. Proportion of participants who achieve British Isles Lupus Assessment Group-based Combined Lupus Assessment (BICLA) response

    Time frame: At week 52

  2. Proportion of participants who achieve both SRI(4) and BICLA (dual responders)

    Time frame: At week 52

  3. Proportion of participants with a Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score ≥ 10 at baseline who achieve a CLASI response, defined as a decrease of ≥ 50% from baseline CLASI activity score

    Time frame: At week 52

  4. Proportion of participants who achieve Lupus Low Disease Activity State (LLDAS)

    Time frame: At week 52

  5. Proportion of participants with ≥ 6 active (tender + swollen) joints at baseline who achieve at least 50% from baseline reduction in active (tender + swollen) joints

    Time frame: At week 52

  6. Change from baseline in patient-reported fatigue according to Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue

    Time frame: At week 52

  7. Proportion of participants with oral corticosteroid (OCS) ≥ 7.5 mg/day of prednisone at baseline who are receiving ≤ 5 mg/day of prednisone at Week (Wk) 40 which is maintained through Wk52 and who achieve an SRI(4) response at Wk52.

    Time frame: At Week 52

  8. Number of participants with adverse events (AEs)

    Time frame: Up to 156 weeks

  9. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 156 weeks

  10. Number of participants with AEs leading to discontinuation of treatment

    Time frame: Up to 156 weeks

  11. Number of participants with AEs leading to study discontinuation

    Time frame: Up to 156 weeks

  12. Number of participants with target adverse events of special interest (AESIs)

    Time frame: Up to 156 weeks

  13. Number of participants with laboratory abnormalities

    Time frame: Up to 156 weeks

  14. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 156 weeks

  15. Number of participants with vital sign abnormalities

    Time frame: Up to 156 weeks

07

Study locations

197 sites
  • Local Institution - 0012
    Birmingham, Alabama 35205, United States
  • Local Institution - 0229
    Phoenix, Arizona 85006, United States
  • Local Institution - 0193
    Tucson, Arizona 85724, United States
  • Kaiser Permanente
    Fontana, California 92335, United States
  • Local Institution - 0247
    La Mesa, California 91942, United States
  • Local Institution - 0090
    La Palma, California 90623, United States
  • Local Institution - 0124
    Los Angeles, California 90095, United States
  • Local Institution - 0248
    Sacramento, California 95817, United States
  • Local Institution - 0253
    San Diego, California 92128, United States
  • Local Institution - 0128
    Santa Barbara, California 93108, United States
  • Local Institution - 0099
    Denver, Colorado 80230, United States
  • Local Institution - 0054
    New Haven, Connecticut 06510, United States
  • Local Institution - 0249
    Coral Springs, Florida 33065, United States
  • Local Institution - 0010
    Gainesville, Florida 32610, United States
  • Local Institution - 0087
    Miami, Florida 33136, United States
  • Local Institution - 0007
    Orlando, Florida 32806, United States
  • Local Institution - 0242
    Plantation, Florida 33317, United States
  • Local Institution - 0002
    Tamarac, Florida 33321, United States
  • Local Institution - 0165
    Tampa, Florida 33614, United States
  • Local Institution - 0204
    Atlanta, Georgia 30318, United States
  • Local Institution - 0228
    Lawrenceville, Georgia 30044, United States
  • Local Institution - 0147
    Lawrenceville, Georgia 30046, United States
  • Local Institution - 0227
    Morton Grove, Illinois 60053, United States
  • Local Institution - 0077
    Schaumburg, Illinois 60195, United States
  • Local Institution - 0108
    Indianapolis, Indiana 46202, United States
  • Lake Cumberland Rheumatology
    New Albany, Indiana 47150, United States
  • Local Institution - 0225
    New Orleans, Louisiana 70121, United States
  • Local Institution - 0006
    Detroit, Michigan 48202, United States
  • Local Institution - 0179
    Eagan, Minnesota 55121, United States
  • Local Institution - 0177
    Summit, New Jersey 07901, United States
  • Local Institution - 0180
    Manhasset, New York 11030, United States
  • Local Institution - 0085
    New York, New York 10016, United States
  • Local Institution - 0098
    Rochester, New York 14642, United States
  • Local Institution - 0159
    The Bronx, New York 10467, United States
  • Local Institution - 0245
    Charlotte, North Carolina 28207, United States
  • Local Institution - 0155
    Charlotte, North Carolina 28211, United States
  • Local Institution - 0246
    Summerville, South Carolina 29486, United States
  • Local Institution - 0003
    Memphis, Tennessee 38119, United States
  • Local Institution - 0064
    Allen, Texas 75013, United States
  • Local Institution - 0065
    Dallas, Texas 75390, United States
  • Local Institution - 0088
    Fort Worth, Texas 76177, United States
  • Local Institution - 0250
    Houston, Texas 77090, United States
  • Local Institution - 0219
    Lubbock, Texas 79415, United States
  • Local Institution - 0005
    The Woodlands, Texas 77382, United States
  • Local Institution - 0009
    Roanoke, Virginia 24016, United States
  • Local Institution - 0011
    Seattle, Washington 98122, United States
  • Local Institution - 0139
    Seattle, Washington 98195, United States
  • Local Institution - 0063
    Franklin, Wisconsin 53132, United States
  • Local Institution - 0078
    Quilmes, Buenos Aires 1878, Argentina
  • Local Institution - 0013
    Buenos Aires, Buenos Aires F.D. C1121ABE, Argentina
  • Local Institution - 0020
    CABA, Buenos Aires F.D. 1406, Argentina
  • Local Institution - 0123
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0032
    Buenos Aires, 1123, Argentina
  • Local Institution - 0240
    Buenos Aires, C1023AAB, Argentina
  • Local Institution - 0022
    Buenos Aires, C1221ADC, Argentina
  • Local Institution - 0140
    Buenos Aires, CP1280AEB, Argentina
  • Local Institution - 0138
    Córdoba, 5004, Argentina
  • Local Institution - 0017
    Mendoza, 5500, Argentina
  • Local Institution - 0224
    Salvador, Estado de Bahia 40150-150, Brazil
  • Local Institution - 0096
    Lago Sul, Federal District 71635580, Brazil
  • Local Institution - 0042
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Local Institution - 0041
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Local Institution - 0190
    Curitiba, Paraná 80730-150, Brazil
  • Local Institution - 0181
    Porto Alegre, Rio Grande do Sul 90610000, Brazil
  • Local Institution - 0185
    Campinas, São Paulo 13015-001, Brazil
  • Local Institution - 0187
    Ribeirão Preto, São Paulo 14051-140, Brazil
  • Local Institution - 0066
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Local Institution - 0191
    São Paulo, São Paulo 04038-002, Brazil
  • Local Institution - 0186
    Rio de Janeiro, 20551-030, Brazil
  • Local Institution - 0125
    São Paulo, 05403-000, Brazil
  • Local Institution - 0163
    Plovdiv, 4000, Bulgaria
  • Local Institution - 0217
    Sofia, 1407, Bulgaria
  • Local Institution - 0162
    Sofia, 1784, Bulgaria
  • Local Institution - 0126
    Calgary, Alberta T2N 4N1, Canada
  • Local Institution - 0160
    Hamilton, Ontario L8S 4K1, Canada
  • Local Institution - 0114
    London, Ontario N6A 4V2, Canada
  • Local Institution - 0115
    Toronto, Ontario M5T 2S8, Canada
  • Local Institution - 0136
    Rimouski, Quebec G5L 5T1, Canada
  • Local Institution - 0110
    Bengbu, Anhui 233017, China
  • Local Institution - 0070
    Beijing, Beijing Municipality 100730, China
  • Local Institution - 0107
    Xiamen, Fujian 361003, China
  • Local Institution - 0029
    Guangzhou, Guangdong 510000, China
  • Local Institution - 0051
    Guangzhou, Guangdong 510080, China
  • Local Institution - 0080
    Guangzhou, Guangdong 510120, China
  • Local Institution - 0037
    Shenzhen, Guangdong 518020, China
  • Local Institution - 0153
    Baoding, Hebei 071030, China
  • Local Institution - 0133
    Luoyang, Henan 471003, China
  • Local Institution - 0023
    Zhengzhou, Henan 450000, China
  • Local Institution - 0137
    Wuhan, Hubei 430022, China
  • Local Institution - 0044
    Changsha, Hunan 410008, China
  • Local Institution - 0021
    Zhuzhou, Hunan 412007, China
  • Local Institution - 0089
    Hohhot, Inner Mongolia 010050, China
  • Local Institution - 0129
    Changzhou, Jiangsu 213003, China
  • Local Institution - 0031
    Jiujiang, Jiangxi 332000, China
  • Local Institution - 0071
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0117
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0220
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0028
    Pingxiang, Jiangxi 337055, China
  • Local Institution - 0039
    Shenyang, Liaoning 110001, China
  • Local Institution - 0092
    Shenyang, Liaoning 110004, China

Showing the first 100 of 197 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Arriens C, Morand EF, Askanase AD, Furie R, van Vollenhoven RF, Tanaka Y, Connors K, Davey M, Young K, Franchin G, Meier R, Shah V, de Oliveria CL, Hobar C. Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus. Adv Ther. 2025 Nov;42(11):5830-5844. doi: 10.1007/s12325-025-03299-0. Epub 2025 Sep 8. PubMed 40920289 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Oct 2026, 45 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Nov 15, 2022
StartActual
Jan 12, 2023
Primary completionEst.
Oct 19, 2026
CompletionEst.
Nov 13, 2028
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05617677
Responsible party
Sponsor
First posted
Nov 15, 2022
Start date
Jan 12, 2023
Primary completion
Oct 19, 2026 (estimated)
Completion
Nov 13, 2028 (estimated)
Last update
Dec 3, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion